177 related articles for article (PubMed ID: 35256178)
1. Non-surgical Interventions for Pituitary Lesions.
Suda N
Otolaryngol Clin North Am; 2022 Apr; 55(2):287-304. PubMed ID: 35256178
[TBL] [Abstract][Full Text] [Related]
2. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
3. Update on the medical management of pituitary adenomas.
Pickett CA
Curr Neurol Neurosci Rep; 2005 May; 5(3):178-85. PubMed ID: 15865883
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
5. The treatment algorithm of acromegaly.
Colao A; Pivonello R; Cappabianca P; Vitale G; Lombardi G
J Endocrinol Invest; 2003; 26(8 Suppl):39-45. PubMed ID: 15233211
[No Abstract] [Full Text] [Related]
6. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
7. Current therapy and drug pipeline for the treatment of patients with acromegaly.
Kumar SS; Ayuk J; Murray RD
Adv Ther; 2009 Apr; 26(4):383-403. PubMed ID: 19444656
[TBL] [Abstract][Full Text] [Related]
8. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
Cuny T; Barlier A; Feelders R; Weryha G; Hofland LJ; Ferone D; Gatto F
Ann Endocrinol (Paris); 2015 Feb; 76(1):43-58. PubMed ID: 25556152
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pituitary tumors: somatostatin.
Tichomirowa MA; Daly AF; Beckers A
Endocrine; 2005 Oct; 28(1):93-100. PubMed ID: 16311415
[TBL] [Abstract][Full Text] [Related]
10. Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours.
Colao A; Filippella M; Pivonello R; Di Somma C; Faggiano A; Lombardi G
Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S57-S63. PubMed ID: 17413190
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline in acromegaly.
Kuhn E; Chanson P
Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
13. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds.
Zatelli MC; Ambrosio MR; Bondanelli M; Uberti ECD
Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S29-S35. PubMed ID: 17413185
[TBL] [Abstract][Full Text] [Related]
14. Evidence for dopamine agonists in the treatment of acromegaly.
Jaquet P
J Endocrinol; 1997 Oct; 155 Suppl 1():S59-60. PubMed ID: 9389998
[No Abstract] [Full Text] [Related]
15. Comparison of efficacy and tolerability of somatostatin analogs and other therapies for acromegaly.
Burt MG; Ho KK
Endocrine; 2003 Apr; 20(3):299-305. PubMed ID: 12721511
[TBL] [Abstract][Full Text] [Related]
16. Multimodality treatment of pituitary adenomas.
Oyesiku NM
Clin Neurosurg; 2005; 52():234-42. PubMed ID: 16626076
[No Abstract] [Full Text] [Related]
17. [New medical treatments in pituitary adenomas].
Drutel A; Caron P; Archambeaud F
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
[TBL] [Abstract][Full Text] [Related]
18. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
Melmed S; Sternberg R; Cook D; Klibanski A; Chanson P; Bonert V; Vance ML; Rhew D; Kleinberg D; Barkan A
J Clin Endocrinol Metab; 2005 Jul; 90(7):4405-10. PubMed ID: 15827109
[TBL] [Abstract][Full Text] [Related]
19. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
Gatto F; Barbieri F; Gatti M; Wurth R; Schulz S; Ravetti JL; Zona G; Culler MD; Saveanu A; Giusti M; Minuto F; Hofland LJ; Ferone D; Florio T
Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
[TBL] [Abstract][Full Text] [Related]
20. New perspectives in the medical treatment of acromegaly.
Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
